Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2025-04-02

FDA Approved: ORACEA — Supplemental Application (Galderma Laboratories, L.P.)

View source ↗

Summary

The FDA approves a supplemental application for ORACEA (doxycycline) from Galderma Laboratories, L.P.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • ORACEA (Doxycycline)

Snippet

SUPPL AP for ORACEA (DOXYCYCLINE)